Abstract
PNP deficiency is an autosomal recessive metabolic disorder characterized by severe combined immunodeficiency and by complex neurological symptomatology including ataxia, developmental delay and spasticity. Patients usually die in the first or second decade of life due to recurrent infections. The only curative treatment is bone marrow transplantation (BMT). We describe a 22-month-old girl who underwent BMT from her HLA-identical brother. Conditioning consisted of busulfan and fludarabine only, resulting in low toxicity and prompt engraftment. At 18 months after BMT, the girl has developed normal immunological functions, and her neurological status has improved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / toxicity
-
Bone Marrow Transplantation*
-
Busulfan / administration & dosage
-
Busulfan / toxicity
-
Family Health
-
Female
-
Graft Survival
-
Humans
-
Immunophenotyping
-
Infant
-
Lymphocyte Activation / drug effects
-
Metabolism, Inborn Errors / diagnosis
-
Metabolism, Inborn Errors / enzymology
-
Metabolism, Inborn Errors / therapy*
-
Pregnancy
-
Purine-Nucleoside Phosphorylase / blood
-
Purine-Nucleoside Phosphorylase / deficiency*
-
T-Lymphocytes / cytology
-
Transplantation Conditioning / methods
-
Transplantation Conditioning / standards
-
Transplantation, Isogeneic
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives*
-
Vidarabine / toxicity
Substances
-
Purine-Nucleoside Phosphorylase
-
Vidarabine
-
Busulfan
-
fludarabine